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Abstract
Background: Malaria diagnosis is vital to efficient control programmes and the recent advent of
malaria rapid diagnostic tests (RDTs) provides a reliable and simple diagnostic method. However a
characterization of the efficiency of these tests and the proteins they detect is needed to maximize
RDT sensitivity.
Methods: Plasmodial lactate dehydrogenase (pLDH) gene of wild isolates of the four human
species of Plasmodium from a variety of malaria endemic settings were sequenced and analysed.
Results: No variation in nucleotide was found within Plasmodium falciparum, synonymous
mutations were found for Plasmodium malariae and Plasmodium. vivax; and three different types of
amino acid sequence were found for Plasmodium ovale. Conserved and variable regions were
identified within each species.
Conclusion: The results indicate that antigen variability is unlikely to explain variability in
performance of RDTs detecting pLDH from cases of P. falciparum, P. vivax or P. malariae malaria,
but may contribute to poor detection of P. ovale.
Background
Rapid and reliable diagnosis is one of the key factors in
promoting malaria control. The gold standard for malaria
diagnosis remains the examination of Giemsa-stained
smears by light microscopy. Whilst this standard has a
good sensitivity and specificity and allows species and
stage differentiation, it does require the expertise of a
trained and experienced microscopist, is time-consuming
(30 minutes per diagnostic) and requires equipment not
always available or maintainable in remote areas. The
1990's have seen the advent of a new rapid diagnostic
method, the immunochromatography-based malaria
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Rapid Diagnostic Tests (RDTs). These assays are fast
(revealed in 15 minutes) and, for the most part, very sim-
ple to use. Moreover with the change of therapeutic prac-
tice towards relatively expensive artemisinin-based
combination therapies [1], a good diagnostic has become
essential to limit inappropriate treatment and the devel-
opment of resistance. Although the use of RDTs has
spread, their reliability is still questioned in numerous
studies [2,3]. These assays detect one or several antigens,
the most common are: histidine-rich protein-2 (HRP-2),
aldolase and lactate dehydrogenase (pLDH).
Lactate dehydrogenase is an enzyme that catalyzes the
inter-conversion of lactate into pyruvate. This enzyme is
essential for energy production in Plasmodium [4]. The
level of pLDH in the blood has been directly linked to the
level of parasitaemia [5].
The genetic diversity of HRP2 has been examined and
partly linked to RDT detection sensitivity [6], the genetic
variability has also been assessed in aldolase, it has been
ruled out as a possible cue for variation RDT sensitivity
[7]. Here is the first study of Plasmodium LDH genetic var-
iability as a possible cause of variation in sensitivity of
RDTs.
Methods
A total of eight Plasmodium species (Plasmodium falci-
parum, Plasmodium vivax, Plasmodium. ovale, Plasmodium
malariae, Plasmodium yoeli, Plasmodium chabaudi, Plasmo-
dium berghei and Plasmodium. reichnowi), including the
four human pathogens, from numerous origins (Figure 1)
were examined with a nested-PCR assay amplifying a 543
bp fragment: corresponding to the 57 to 237 amino acid
position of the reference P. falciparum LDH coding
sequence (pf13_0141). All field samples analysed were
Worldwide distribution of the isolate sequenced in the study, grouped by speciesFigure 1
Worldwide distribution of the isolate sequenced in the study, grouped by species. One dot corresponds to one isolate, in red 
the malaria endemic area.
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diagnosed by microscopic examination and confirmed by
PCR [8] and conserved from previous studies and
approved at the time by respective National Ethics Com-
mittees. Two sets of PCR and nested primers were
designed for this study based on the sequences available
on GenBank (Table 1) one set use for P. vivax and P. falci-
parum, and the other for P. ovale and P. malariae.
Forty PCR cycle were undertaken using 94°C for 30 s,
55°C for 60 s and 72°C for 75 s; the same cycle was used
for the nested-PCR but only repeated 35 times. Positive
and negative controls were included in all amplification
assays. The amplified products were purified using a Qui-
aquick PCR purification kit (QIAGEN, Valencia, CA)
according to the manufacturer's recommendations, and
sequenced using Big Dye Terminator kit v1.1 (Applied
Biosystems, Foster City, CA) in an AbiPrism 3130
sequencing machine (Applied Biosystems, Foster City,
CA).
Results
No variability was observed in P. falciparum (n = 49) with
a homology of 100% between all newly sequenced
sequences (named F). A single reference sequence on Gen-
Bank (corresponding to the FCC1/HN strain) exhibited a
different amino acid sequence (named F1). For P. vivax (n
= 10), four different types of sequence were found, the
mutations observed were all synonymous (named V); no
geographic pattern was identified. P. malariae (n = 17)
exhibited three different type of sequences, one for African
and American isolates and the other two for the south-east
Asian isolate and reference strain respectively. Those vari-
ations resulted in the same amino acid sequence (named
M).
P. ovale (n = 13) exhibited three different types of nucle-
otide sequences, leading to three different types of amino
acid sequences (named O1, O2 and O3). P. berghei and P.
yoeli sequences exhibited synonymous mutations (named
Y). P. chabaudi exhibited a nucleotide sequence (named
C).P. reichnowi and P. falciparum sequences exhibited syn-
onymous mutations.
Interestingly a comparison of the sequences of different
species reveals the existence of conserved regions and
other very variable ones; this inter-specific variation is
exhibited in Figure 2. Table 2 gives details of the analysed
isolates.
Discussion
Here is described, for the first time, the sequence variabil-
ity of pLDH in the four human's species of malaria and
four animal Plasmodium species and analysed them
together with published sequences. The results indicate
the existence of both variable and conserved regions in
plasmodial lactate dehydrogenase.
The intra-specific geographic conservation of pLDH sug-
gests that genetic variability may not be linked to dispari-
ties in sensitivities or specificities observed in the
detection of P. falciparum [3] with anti-pan LDH antibod-
ies. The falciparum-specific epitope detected by RDTs is
probably situated in the inter-specific variable regions we
have identified; whilst the pan-malarial epitope is more
likely situated in a conserved region. However, Moody et
al. [2] reported that one pan-specific monoclonal anti-
body used in a pLDH RDT has a lower affinity to P. malar-
iae and P. ovale antigens, the attribution of this to a
sequence divergence must not be neglected and should be
further investigated.
Conclusion
The WHO states: "Rapid diagnostic tests (RDTs) offer the
potential to provide accurate diagnosis to all at risk popu-
lations (...) The success of RDTs in malaria control will
depend on good quality planning and implementation"
[9]. Moreover a rapid diagnostic test needs to be reliable
globally, to detect an antigen that mirrors accurately
blood parasitaemia; therefore part of a good quality assur-
ance is to monitor such factors.
Schematic representation of the 181 amino acid sequence variation (each different marks correspond to one amino acid change)Figur  2
Schematic representation of the 181 amino acid sequence 
variation (each different marks correspond to one amino acid 
change). F, F1, M, V, O1, O2, O, Y and C correspond to the 
sequence identified in the study (see result). The conserved 
regions of the Plasmodium pLDH gene for all species are high-
lighted in green.
Table 1: PCR and nested-PCR primers used in the study
PCR primers Primer sequence 5' to 3'
Fv1 ATGATYGGAGGMGTWATGGC
Fv2 GCCTTCATYCTYTTMGTYTC
Mo1 ATGATWGGAGGTGTTATGGC
Mo2 TGTGTCCRTATTGDCCTTC
Nested Primers
Fv1n AATGTKATGGCWTATTCMAATTGC
Fv2n AACRASAGGWGTACCACC
Mo1n TAGGMGATGTTGTTATGTTYG
Mo2n ATTTCRATAATAGCAGCAGC
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Table 2: Result of the sequence analysis for the isolates tested in this paper.
ID Code Year species Origin Seq AA
5353A 2005 PF South Africa F F
5353B 2005 PF South Africa F F
5421 2005 PF Benin F F
5445 2005 PF Brazil F F
4899 2004 PF Burkina Faso F F
CAMBF 2001 PF Cambodia F F
5203 2005 PF Cameroon F F
5848 2005 PF Cap Verde F F
5265 2005 PF Republic of Central Africa F F
3414 2002 PF Colombia F F
4682 2004 PF Comoros F F
5405 2005 PF Congo F F
4919 2004 PF Ivory Cost F F
5600 2005 PF Dominican Republic F F
1628 1999 PF Ecuador F F
5648 2005 PF Gabon F F
5083 2004 PF Gambia F F
5094 2004 PF Ghana F F
5898 2005 PF Guinea F F
5339 2005 PF Equatorial Guinea F F
FguyF 2003 PF French Guiana F F
5555 2005 PF Haiti F F
5745 2005 PF India F F
2038 2000 PF Kenya F F
4548 2004 PF Liberia F F
4609 2004 PF Madagascar F F
2686 2001 PF Malaysia F F
5296 2005 PF Malawi F F
5173 2004 PF Mali F F
5793 2005 PF Mali F F
4807 2004 PF Mauritania F F
4629 2004 PF Mozambique F F
5323 2005 PF Namibia F F
5822 2005 PF Niger F F
4582 2004 PF Nigeria F F
5846 2005 PF Pakistan F F
1317 1998 PF Papua New Guinea F F
5225 2005 PF Sao Tome F F
4838A 2004 PF Senegal F F
4512 2004 PF Sierra Leone F F
4764 2004 PF Sir Lanka F F
4562 2004 PF Sudan F F
5224 2005 PF Tanzania F F
5647 2005 PF Chad F F
604 1997 PF Thailand F F
4751A 2004 PF Togo F F
4751B 2004 PF Togo F F
542 1997 PF Yemen F F
5197 2005 PF Congo Democratic Republic F F
ID Code Year species Origin Seq AA
Plasmodium malariae
CAMBM 2001 PM Cambodia M2 M
3413 2002 PM Cameroon M3 M
4739 2004 PM Cameroon M3 M
5990 2006 PM Cameroon M3 M
1909 1999 PM Republic of Central Africa M3 M
3670 2002 PM Comoros M3 M
4014 2003 PM Comoros M3 M
1548 1999 PM Congo M3 M
2667 2001 PM Ivory Cost M3 M
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As part of this quality assurance, we have identified that
an intra-specific genetic variability is not a significant fac-
tor in the variation of efficiency observed in rapid diag-
nostic tests in the detection of P. falciparum, P vivax and P.
malariae, although it may explain the poor sensitivity to P.
ovale [7]. Similar findings of low variability have been
demonstrated for plasmodial aldolase another target anti-
gen of MRDTs [10] despite a bad sensitivity in the dectec-
tion of P. ovale infection [11] in contrast to HRP2, a target
antigen of P. falciparum with high variability affecting
MRDT sensitivity. In this regard, pLDH offers advantages
as a target antigen for diagnosis. The identification of pan-
specific and species-specific regions may help in develop-
ment of more sensitive and specific monoclonal antibod-
ies for MRDTs.
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5041 2004 PM Ivory Cost M3 M
4568 2004 PM French Guiana M3 M
4774 2004 PM Madagascar M3 M
516 1997 PM Senegal M3 M
1018 1998 PM Togo M3 M
2389 2000 PM Congo Democratic Republic M3 M
Plasmodium ovale
5894 2005 PO Angola O2 O2
CAMBO 2001 PO Cambodia O2 O2
3044 2001 PO Republic of Central Africa O2 O2
5979 2006 PO Ivory Cost O2 O2
3149 2002 PO Gabon O2 O2
4646 2004 PO Guinea O2 O2
3740 2002 PO Congo Democratic Republic O2 O2
4419 2003 PO Cameroon O3 O3
5401 2005 PO Madagascar O3 O3
2132 2000 PO Mali O3 O3
5994 2006 PO Mali O3 O3
2668 2001 PO Rwanda O3 O3
3043 2001 PO Zimbabwe O3 O3
Plasmodium vivax
3019 2001 PV French Guiana V1 V
1977 2000 PV India V1 V
1866 1999 PV Nicaragua V1 V
800 1997 PV Thailand V1 V
2642 2001 PV Madagascar V2 V
5315 2005 PV Chine V3 V
CAMBV 2001 PV Cambodia V4 V
5753 2005 PV Comoros V4 V
1173 1998 PV Laos V4 V
ID Code species Origin Seq AA
Reference strains
3D7 PF pf13_0141 F F
FCC1/HN PF dq825436 F1 F
EMBL PM ay486059 M1 M
EMBL PO ay486058 O1 O1
EMBL PV ay486060 V1 V
YOELII PY xm_719008 Y Y
CHABAUDI PC xm_740087 C C
BERGHEI PB ay437808 B Y
REICHNOWII PR ab122147 R F
Seq = Nucleotide sequence, AA = aminoacid sequence
Table 2: Result of the sequence analysis for the isolates tested in this paper. (Continued)
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